Journal article
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration*
Abstract
OBJECTIVES: To determine the severity of injection site reactions (ISRs), patient quality of life (QoL) and preference when enfuvirtide is administered by the Biojector (Bioject, Medical Technologies, Inc., Tualatin, OR, USA) relative to standard needles.
METHODS: A total of 201 HIV-positive patients on stable enfuvirtide-based therapy (n=184) or initiating such therapy (n=17) were evaluated prospectively after switching from standard needles …
Authors
Loutfy; Harris M; Raboud J; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A
Journal
HIV Medicine, Vol. 8, No. 7, pp. 427–432
Publisher
Wiley
Publication Date
10 2007
DOI
10.1111/j.1468-1293.2007.00489.x
ISSN
1464-2662